EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Arkema SA (AKE) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Arkema SA €71.98, price €57.50, upside +25.2%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Basic Materials · FR · ISIN FR0010313833

AS Arkema SA logo Broad data Sep 24, 2026

Arkema SA

AKE · PA

SpeculativeUpside exists, but weak quality makes the signal speculative.

Fair value €71.98 · Undervalued (+25%)
!Quality 49/100
!Weak Growth (revenue 5y +2.8 %/yr)
!Thin margins · 0.5% net margin (TTM)
Moderate debt · generates free cash flow
·6.26% dividend yield
!Mixed vs. peers (6/15)
!Narrow moat 27/100
!Weak on past: 2 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€108.35 €45.66 Fair Value €71.98 Jul 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range €45.66 – €108.35 · fair‑value band €57.91 – €71.98 · the €57.50 price screens below the €71.98 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Arkema in your weekly email

Every Wednesday you see whether Arkema is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Arkema S.A., together with its subsidiaries, manufactures and sells specialty materials in Europe, the United States, Canada, Mexico, China, Hong Kong, Taiwan, and internationally. It operates in three segments: Adhesive Solutions, Advanced Materials and Coating Solutions, and Intermediates.

Show more

Arkema S.A., together with its subsidiaries, manufactures and sells specialty materials in Europe, the United States, Canada, Mexico, China, Hong Kong, Taiwan, and internationally. It operates in three segments: Adhesive Solutions, Advanced Materials and Coating Solutions, and Intermediates. The company provides solutions for construction, renovation of buildings, and DIY; high performance adhesives for durable goods, and adhesive solutions for packaging and non-woven; and supplies technologies used in building activities for businesses and individuals, including sealants, tiles, flooring adhesives and waterproofing systems, and technologies used in automotive, textiles, glazing, flexible and rigid packaging, and hygiene markets. It also offers high performance polymers, such as specialty polyamides, PVDF, polyimides, fluorospecialties, and PEKK; and performance additives comprising interface agents combining specialty surfactants, molecular sieves, organic peroxides, thiochemicals, and hydrogen peroxide. In addition, the company provides lightweighting, new energies, access to water, bio-based products, and recycling solutions for automotive and transportation sectors, oil and gas, renewable energies, consumer goods, electronics, construction, coatings, animal nutrition and water treatment. Further, it offers coating solutions, including EU/US acrylics and coating resins; coating additives, such as sartomer photocure resins, and coatex rheology additives and specialties; decorative paints, industrial coatings, and adhesives; and solutions for applications in the paper, superabsorbent, water treatment and oil and gas extraction, and 3D printing and electronics markets. Additionally, the company provides fluorogases and asia acrylics; and industrial intermediate chemicals for construction, refrigeration and air conditioning, automotive, coatings, and water treatment sectors. Arkema S.A. was incorporated in 2003 and is headquartered in Puteaux, France.

Stock analysis

Arkema SA (AKE) currently trades at €57.50, while our model-based Fair Value estimate is €71.98, implying the stock looks roughly 20.1% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of €55.03 per share, and 4 of the 24 models we run sit above the €57.50 price.

Bear case: the Earnings-Based group reads lowest at €9.85, and 20 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: €57.91 (bear) to €71.98 (bull), the price of €57.50 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Basic Materials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Arkema SA reported revenue of €9.1B in FY2025 versus €9.5B in FY2021, a compound −1.2%/yr. Reported net income was €63.0M in FY2025, compounding −53.2%/yr from FY2021.

Key figures

Market cap €4.4B · P/E ratio 250.0 · P/S ratio 1.74 · EPS (TTM) €0.2300 · Dividend yield 6.3% · Net margin 0.7% · Return on equity 0.5% · Return on assets (EBIT) 5.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).

What moves the price

The share trades about 9% below its 52-week high and 26% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −48% fair-value upside, at 25%, AKE screens cheaper than that median.

Fair Value models

Bear €57.91 Fair Value €71.98 Bull €71.98
Model Each model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence Evidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF €37.65 €56.12 €89.47 79
Growth DCF €39.56 €57.40 €87.15 78
Residual Income €54.15 €50.89 €36.52 76
All 24 models by family
DCF Models
FCF DCF €37.65 €56.12 €89.47 79
Owner Earnings €27.57 €42.66 €69.92 75
5Y Revenue Exit €32.52 €54.02 €84.87 71
5Y EBITDA Exit €69.44 €117.02 €179.05 74
5Y P/E Exit €9.54 €14.80 €21.19 70
10Y Revenue Exit €32.77 €51.59 €73.07 66
10Y EBITDA Exit €56.30 €92.34 €134.03 68
10Y P/E Exit €20.27 €26.23 €31.85 65
Earnings-Based
Graham-Dodd €5.66 €9.85 €12.07 66
EPV €20.94 €27.01 €32.25 74
Dividend Discount
Gordon GGM €31.57 €39.77 €48.02 69
DDM Multi-Stage €31.57 €42.09 €54.44 67
Multiples
P/E Multiple €10.61 €14.15 €17.69 63
P/S Multiple €10.61 €14.15 €17.69 58
P/B Multiple €10.61 €14.15 €17.69 55
EV/EBIT €40.78 €60.20 €79.63 65
EV/EBITDA €106.48 €147.81 €189.13 67
EV/Revenue €33.01 €54.65 €76.30 52
Asset-Based
NCAV (Graham) €39.93 €53.50 €79.85 54
Growth DCF
Growth DCF €39.56 €57.40 €87.15 78
Rev-Margin DCF €32.52 €55.03 €82.86 72
Economic Profit
Residual Income €54.15 €50.89 €36.52 76
ROIC Compounder €20.94 €27.01 €32.25 72
Growth Earnings
Growth-Adj P/E €7.56 €10.80 €14.04 67

Open the full fair value analysis →

Notify me when AKE reaches fair value

Put AKE on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 49/100

Of which business quality 48 · Market factors (momentum, volatility) 56

Profitability 23
Margins and returns on capital today
Quality Growth 32
Are margins and returns improving?
Cashflow 44
Earnings quality: real cash, not paper profit
Fin. Strength 49
Balance sheet, leverage, solvency risk
Investment 88
Disciplined investing over empire-building
Low Volatility 62
Calm price path (market factor)
Momentum 50
Price trend over the last 3–12 months (market factor)
52W Momentum 57
Distance to the 52-week high (market factor)
Net Issuance 73
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality Growth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−5.0%
Revenue growth 3 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.7%
Revenue growth 5 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
Start year 2020 (pandemic). Over 10 years: +1.7% a year
Revenue growth 24 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
What shareholders gained per year (last 5 years) What the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−28.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−34.9%
Dividend (yield on the price)6.3%
Pace: 5 vs 10 years Two data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−35% vs −14%, slowing
Profit margin 2020 to 2025 Operating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 5%
Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes This turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect Analysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+2.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +7.3% a year for the price and +0.1% for the forecasts.
Forecast 2026 (sales)+0.9%
Forecast 2027 (sales)+2.8%
Projected 2028 (sales)+2.7%
Projected 2029 (sales)+2.6%
Projected 2030 (sales)+2.5%

Watch AKE, get fair value alerts →

Recent news

News mood News mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Negative
Recent news coverage is more negative than average.

Compare Arkema SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 719 stocks

Beats the industry median on 6/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside +25% · Top 25%
Profitability
Return on equity (TTM) 1% · Below median
Return on assets 2% · Below median
Net margin (TTM) 0% · Below median
Operating margin (TTM) 3% · Below median
Growth and dividend
Revenue growth −8% · Bottom 25%
Dividend yield (TTM) 6.3% · Top 25%
Balance sheet
Debt / equity 0.58× · Highest 25%

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/E (TTM) 250.0× · Priciest 25%
P/B 0.82× · Cheapest 25%
P/S (TTM) 0.56× · Cheaper than median
P/FCF 14.8× · Priciest 25%
EV/EBITDA 5.7× · Cheapest 25%
PEG 0.47× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)67 · sector 1
FUTURE (revenue growth)0 · sector 21
PAST (return on equity)2 · sector 23
HEALTH (low debt)71 · sector 95
DIVIDEND (yield)100 · sector 29

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Linde plc LIN $464.91 $441.28 −5%
The Sherwin-Williams Company SHW $328.35 $148.97 −55%
Ecolab Inc ECL $276.22 $96.18 −65%
Air Products and Chemicals, Inc APD $287.86 $122.14 −58%
Givaudan SA GIVN CHF 3,464 CHF 1,523 −56%
Wanhua Chemical Group 600309 ¥70.66 ¥68.03 −4%
Sika AG SIKA CHF 188.90 CHF 98.89 −48%
Asian Paints Limited ASIANPAINT ₹2,449 ₹1,479 −40%
PPG Industries, Inc PPG $107.77 $77.06 −28%
DSM-Firmenich AG DSFIR CHF 91.50 CHF 29.27 −68%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Arkema SA Fair Value". https://www.fairvalue-calculator.com/stock/AKE

Frequently asked questions

Is Arkema SA (AKE) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €71.98 versus a price of €57.50, about +25% upside (undervalued).
What is the fair value of AKE?
Our model-based fair value for Arkema SA is €71.98 (as of Sep 24, 2026), built from audited fundamentals. The current price: €57.50.
What is the quality score of AKE?
Arkema SA has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Arkema SA (AKE)?
Our model-based price target is the fair value of €71.98 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario €57.91, optimistic scenario €71.98. It is a calculation from audited fundamentals, not an analyst target.
What is the Arkema SA stock forecast for 2026?
Our models put fair value at €71.98, about +25% upside versus a price of €57.50 (undervalued). Cautious scenario €57.91, optimistic scenario €71.98. The calculation is refreshed regularly with new filings.
What is the revenue of Arkema SA (AKE)?
Arkema SA reported trailing-twelve-month revenue of about €8.9B (latest available figure, as of Sep 24, 2026).
Does Arkema SA pay a dividend?
Arkema SA currently shows a dividend yield of about 6.26% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Arkema SA (AKE)?
For today's price to be fair in a discounted-cash-flow model, Arkema SA would have to grow free cash flow by +9.6 % per year for five years (discount rate 10.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of AKE use?
Our models discount Arkema SA at 10.2 %: a base by market capitalisation (mid), damped by beta 0.96, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Arkema SA that is +9.6 % per year a year over ten years, using the same discount rate (10.2 %) and the same formula as our fair value.
How much growth has Arkema SA (AKE) delivered so far?
Over the past 5 years revenue at Arkema SA grew +2.8 % a year. The price currently implies +9.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Arkema SA (AKE) growing?
The median revenue growth in the sector is +3.3 % a year. That is the yardstick for the growth priced into Arkema SA (+9.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Arkema SA (AKE)?
The free-cash-flow yield on the price is 7.72 %: that much free cash flow Arkema SA produces per unit of market value. When it exceeds the discount rate of our models (10.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Arkema SA (AKE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Arkema SA it is €71.98 per share (as of Sep 24, 2026), against a price of €57.50. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Arkema SA stock overvalued or undervalued in 2026?
As of Sep 24, 2026, AKE trades below its calculated fair value: price €57.50, fair value €71.98, a gap of about +25% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AKE?
No. The price is what the market pays today (€57.50); the fair value is what the company's own numbers justify (€71.98). For Arkema SA the two are €14.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Arkema SA worth?
The market values Arkema SA at about €4.4B (market capitalisation, as of Sep 24, 2026). Per share that is €57.50; our models calculate a fair value of €71.98 per share.
What do the bullish and bearish scenarios say about AKE?
Our models span a range for Arkema SA: cautious scenario €57.91, base €71.98, optimistic €71.98 per share (as of Sep 24, 2026, price €57.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AKE?
Arkema SA trades at a price-to-earnings ratio of 250.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €71.98 is built from several models across several years. Other multiples: PEG 0.5, P/B 0.8, P/S 0.6, EV/EBITDA 5.7.
What is the PEG ratio of AKE?
The PEG ratio of Arkema SA is 0.47 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Arkema SA (AKE)?
Balance-sheet figures for Arkema SA (as of Sep 24, 2026): return on equity 0.5%, debt of 0.58 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is AKE from its 52-week high?
Arkema SA trades at €57.50, about 9% below its 52-week high of €63.05 and 26% above the low of €45.66 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of €71.98 is for.
Which stocks are comparable to Arkema SA?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Arkema SA stock attractive at the current price?
The data as of Sep 24, 2026: price €57.50, calculated fair value €71.98 (+25%), Quality Score 49/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AKE calculated?
We run Arkema SA through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €71.98, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Arkema SA currently trades 25 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Arkema SA (AKE)?
The closing price on Sep 23, 2026 was €57.50. Our model-based fair value is €71.98, about +25% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Arkema SA right now?
Solid quality (49/100) at a price below fair value, the discount is the argument here, not the business quality. The price sits below our cautious bear case: the market assumes less than even our pessimistic scenario. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Arkema SA (AKE) come from?
Earnings per share at Arkema SA grew −1.3 % a year from 2014 to 2025. Broken into its drivers: revenue per share +2.7 %, EBIT margin −2.3 %, tax rate −0.2 %, residual (interest, one-offs) −1.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Arkema SA

How large is the market capitalisation of Arkema SA (AKE)?
The market capitalisation of Arkema SA is €4.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Arkema SA (AKE)?
The price-to-sales ratio of Arkema SA is 1.74 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Arkema SA (AKE)?
Earnings per share at Arkema SA are €0.2300 (price ÷ EPS = P/E 250.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Arkema SA (AKE)?
The dividend yield of Arkema SA is 6.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Arkema SA (AKE)?
The net margin of Arkema SA is 0.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Arkema SA (AKE)?
The return on equity (ROE) of Arkema SA is 0.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Arkema SA (AKE)?
On an EBIT basis the return on assets of Arkema SA is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Arkema SA (AKE)?
The operating margin of Arkema SA is 3.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Arkema SA (AKE)?
Revenue at Arkema SA is growing −8.4% versus a year earlier (3y avg −7.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Arkema SA (AKE)?
Earnings per share at Arkema SA are growing −84.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Arkema SA (AKE) carry?
The net debt of Arkema SA is €3.2B (fiscal year 2025, ≈ 9.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Arkema SA in the live analysis

One click puts Arkema SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.